- Antitrust Has a Generic-Drug Problem: Brand-name drugmakers like to pay lower-cost rivals not to compete — and courts too often let them. https://www.theatlantic.com/ideas/archive/2023/06/pharmaceutical-generic-drugs-pay-for-delay/674410/ 10 comments economy
Linking pages
Linked pages
- Do Prescription Drugs Really Have to Be So Expensive? - The Atlantic https://www.theatlantic.com/health/archive/2019/03/drug-prices-high-cost-research-and-development/585253/ 140 comments
- Two Generic Medications Become One Expensive Drug - The Atlantic https://www.theatlantic.com/health/archive/2017/06/how-two-common-medications-became-one-455-million-specialty-pill/530808/ 8 comments
- Opinion | FTC Chair Lina Khan on the Problems with Noncompetes - The New York Times https://www.nytimes.com/2023/01/09/opinion/linakhan-ftc-noncompete.html 1 comment
Related searches:
Search whole site: site:www.theatlantic.com
Search title: Pay for Delay: Big Pharma’s Most Maddening Business Tactic - The Atlantic
See how to search.